LAMPERT MARK N Form 3

## FORM 3

May 20, 2009

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement REPLIGEN CORP [RGEN] BVF PARTNERS L P/IL (Month/Day/Year) 05/15/2009 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 900 N. MICHIGAN (Check all applicable) **AVENUE, Â SUITE 1100** (Street) 6. Individual or Joint/Group \_X\_\_ 10% Owner Director Officer \_\_X\_\_ Other Filing(Check Applicable Line) (give title below) (specify below) Form filed by One Reporting Group Member Person CHICAGO, ILÂ 60611 \_X\_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Â  $D^{(1)}$ Common Stock 825,750 Â Common Stock  $D^{(2)}$ 534,400  $D^{(3)}$ Common Stock 1,856,700 General partner and manager of I (4) Common Stock 3,216,850 entities with direct ownership. General partner of entity with Common Stock I (5) 3,216,850 indirect ownership. Sole shareholder and sole director Common Stock I (6) 3,216,850 of entity with indirect ownership.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

### Edgar Filing: LAMPERT MARK N - Form 3

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	Expiration Date		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Radress	Director	10% Owner	Officer	Other		
BVF PARTNERS L P/IL 900 N. MICHIGAN AVENUE SUITE 1100 CHICAGO, IL 60611	Â	ÂX	Â	Group Member		
BIOTECHNOLOGY VALUE FUND L P 900 N. MICHIGAN AVENUE, SUITE 1100 CHICAGO, IL 60611	Â	ÂΧ	Â	Group Member		
BIOTECHNOLOGY VALUE FUND II LP C/O GROSVENOR CAPITAL MANAGEMENT 900 N. MICHIGAN AVENUE, SUITE 1100 CHICAGO, IL 60611	Â	ÂX	Â	Group Member		
BVF INVESTMENTS LLC C/O GROSVENOR CAPITAL MANAGEMENT LP 900 N. MICHIGAN AVENUE, SUITE 1100 CHICAGO, IL 60611	Â	ÂX	Â	Group Member		
BVF INC/IL C/O GROSVENOR CAPITAL MANAGEMENT 900 N. MICHIGAN AVENUE, SUITE 1100 CHICAGO, IL 60611	Â	ÂX	Â	Group Member		
LAMPERT MARK N 2415 GREEN ST SAN FRANCISCO, CA 94123	Â	ÂX	Â	Group Member		

## **Signatures**

BVF PARTNERS L.P., By: BVF Inc., its General Partner, By: /s/ Mark N. Lampert, President

05/20/2009

\*\*Signature of Reporting Person

Date

05/20/2009

Reporting Owners 2

### Edgar Filing: LAMPERT MARK N - Form 3

BIOTECHNOLOGY VALUE FUND, L.P., By: BVF Partners L.P., its General Partner, By: BVF Inc., its General Partner, By: /s/ Mark N. Lampert, President

\*\*Signature of Reporting Person

Date

BIOTECHNOLOGY VALUE FUND II, L.P., By: BVF Partners L.P., its General Partner, By: BVF Inc., its General Partner, By: /s/ Mark N. Lampert, President

05/20/2009

\*\*Signature of Reporting Person

Date

BVF INVESTMENTS, L.L.C., By: BVF Partners L.P., its Manager, By: BVF Inc., its General

Partner, By: /s/ Mark N. Lampert, President

05/20/2009

\*\*Signature of Reporting Person

Date

BVF INC., By: /s/ Mark N. Lampert, President

05/20/2009

\*\*Signature of Reporting Person

Date

Mark N. Lampert, By: /s/ Mark N. Lampert

05/20/2009

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of Common Stock are directly beneficially owned by Biotechnology Value Fund, L.P. ("BVF"), a Delaware limited partnership.
- (2) The shares of Common Stock are directly beneficially owned by Biotechnology Value Fund II, L.P. ("BVF2"), a Delaware limited partnership.
  - The shares of Common Stock are directly beneficially owned by BVF Investments, LLC ("BVFLLC"), a Delaware limited liability company. Pursuant to the operating agreement of BVFLLC, BVF Partners, L.P., a Delaware limited partnership ("Partners") is
- (3) authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVFLLC, in the shares of Common Stock and other securities and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
- (4) The shares of Common Stock are indirectly beneficially owned by Partners. Partners is the general partner of BVF and BVF2 and is the manager of BVFLLC.
- (5) The shares of Common Stock are indirectly beneficially owned by BVF Inc., a Delaware corporation ("BVF Inc."). BVF Inc. is the general partner of Partners.
- (6) Mark N. Lampert is the sole shareholder, sole director, and an officer of BVF Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3